摘要
乳腺癌是女性最常见的恶性肿瘤,发病率位居全球第一。随着靶向药物的出现及乳腺癌系统治疗的完善,早期乳腺癌患者的预后得到极大改善,但是对于多线治疗后和初诊远处转移等难治性乳腺癌患者,单纯的抗体或细胞毒性药物并不能满足治疗需求。抗体药物偶联物(ADCs)是一种通过连接子将细胞毒性药物与单克隆抗体相连接的免疫偶联物,利用靶向肿瘤抗原的单克隆抗体将细胞毒性药物选择性递送至癌细胞,因此具有选择性强、高效低毒等优点。近年来,ADCs在乳腺癌治疗领域占有越来越重要的地位。本文就ADCs的主要作用机制及在乳腺癌领域中的治疗现状及进展作一综述。
Breast cancer is the most common female malignant tumor and has become the most common cancer in the world.With the advent of targeted drugs and the improvement of systemic treatment for breast cancer,the prognosis of patients with early breast cancer has been greatly improved.However,for patients with refractory breast cancer after multi-line therapy and newly diagnosed distant metastasis,the antibodies or cytotoxic drugs alone cannot meet the therapeutic needs.Antibody-drug conjugates(ADCs)are immunoconjugates that connect cytotoxic drugs and monoclonal antibodies via the molecular linker,which can selectively deliver cytotoxic drugs to cancer cells through monoclonal antibodies targeting tumor antigens,and so they have the advantages of strong selectivity,high efficiency and low toxicity.In recent years,ADCs have played an increasingly important role in the treatment of breast cancer.This review summarizes the main mechanism of ADCs,the current status and progress of ADCs for breast cancer.
作者
贺萍
伍雁琦
罗婷
HE Ping;WU Yanqi;LUO Ting(Department of Head and Neck Oncology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《临床肿瘤学杂志》
CAS
2022年第3期255-264,共10页
Chinese Clinical Oncology
关键词
乳腺癌
抗体药物偶联物
疗效
安全性
Breast cancer
Antibody-drug conjugates
Efficacy
Safety
